Publicaciones recientes / Recent Publications:

Vandermeeren AM, Gomez CE, Patino C, Domingo-Gil E, Guerra S, Gonzalez JM and Esteban M. (2008)
Subcellular forms and biochemical events triggered in human cells by HCV polyprotein expression from a viral vector.
Virol J. 5(1):102.

Mooij P, Balla-Jhagjhoorsingh SS, Koopman G, Beenhakker N, van Haaften P, Baak I, Nieuwenhuis IG, Kondova I, Wagner R, Wolf H, Gomez CE, Najera JL, Jimenez V, Esteban M and Heeney JL. (2008)
Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates.
J Virol. 82(6):2975-2988.

Kochan G, Escors D, Gonzalez JM, Casasnovas JM and Esteban M. (2008)
Membrane cell fusion activity of the vaccinia virus A17-A27 protein complex.
Cell Microbiol. 10:149-164.

Harari A, Bart PA, Stohr W, Tapia G, Garcia M, Medjitna-Rais E, Burnet S, Cellerai C, Erlwein O, Barber T, Moog C, Liljestrom P, Wagner R, Wolf H, Kraehenbuhl JP, Esteban M, Heeney J, Frachette MJ, Tartaglia J, McCormack S, Babiker A, Weber J and Pantaleo G. (2008)
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.
J Exp Med. 205(1):63-77.

Guerra S, Caceres A, Knobeloch KP, Horak I and Esteban M. (2008)
Vaccinia virus E3 protein prevents the antiviral action of ISG15.
PLoS Pathog. 4(7):e1000096.

Gomez CE, Najera JL, Krupa M and Esteban M. (2008)
The Poxvirus Vectors MVA and NYVAC as Gene Delivery Systems for Vaccination Against Infectious Diseases and Cancer.
Curr Gene Ther. 8(2):97-120.

Dondji B, Deak E, Goldsmith-Pestana K, Perez-Jimenez E, Esteban M, Miyake S, Yamamura T and McMahon-Pratt D. (2008)
Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania.
Eur J Immunol. 38(3):706-719.

Domingo-Gil E, Perez-Jimenez E, Ventoso I, Najera JL and Esteban M. (2008)
Expression of the E3L gene of vaccinia virus in transgenic mice decreases the host resistance to vaccinia virus and Leishmania major infection.
J Virol. 82:254-267.

Corbett M, Bogers WM, Heeney JL, Gerber S, Genin C, Didierlaurent A, Oostermeijer H, Dubbes R, Braskamp G, Lerondel S, Gomez CE, Esteban M, Wagner R, Kondova I, Mooij P, Balla-Jhagjhoorsingh S, Beenhakker N, Koopman G, van der Burg S, Kraehenbuhl JP and Le Pape A. (2008)
Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic.
Proc Natl Acad Sci U S A. 105(6):2046-2051.

Bart PA, Goodall R, Barber T, Harari A, Guimaraes-Walker A, Khonkarly M, Sheppard NC, Bangala Y, Frachette MJ, Wagner R, Liljestrom P, Kraehenbuhl JP, Girard M, Goudsmit J, Esteban M, Heeney J, Sattentau Q, McCormack S, Babiker A, Pantaleo G and Weber J. (2008)
EV01: A phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium.
Vaccine. 26(25):3153-3161.

Munoz-Fontela C, Garcia MA, Collado M, Marcos-Villar L, Gallego P, Esteban M and Rivas C. (2007)
Control of virus infection by tumour suppressors.
Carcinogenesis. 28(6):1140-1144.

Guerra S, Najera JL, Gonzalez JM, Lopez-Fernandez LA, Climent N, Gatell JM, Gallart T and Esteban M. (2007)
Distinct Gene Expression Profiling after Infection of Immature Human Monocyte-Derived Dendritic Cells by the Attenuated Poxvirus Vectors MVA and NYVAC.
J Virol. 81(16):8707-8721.

Gomez CE, Najera JL, Jimenez V, Bieler K, Wild J, Kostic L, Heidari S, Chen M, Frachette MJ, Pantaleo G, Wolf H, Liljestrom P, Wagner R and Esteban M. (2007)
Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
Vaccine. 25(11):1969-1992.

Gomez CE, Najera JL, Jimenez EP, Jimenez V, Wagner R, Graf M, Frachette MJ, Liljestrom P, Pantaleo G and Esteban M. (2007)
Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
Vaccine. 25(15):2863-2885.

Gomez CE, Najera JL, Domingo-Gil E, Ochoa-Callejero L, Gonzalez-Aseguinolaza G and Esteban M. (2007)
Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice.
J Gen Virol. 88(Pt 9):2473-2478.

Garcia MA, Muñoz-Fontela C, Collado M, Marcos-Villar L, Esteban M and Rivas C. (2007)
Novel and unexpected role for the tumor suppressor ARF in viral infection surveillance.
Future Virology. 2:625-629.

Garcia MA, Meurs EF and Esteban M. (2007)
The dsRNA protein kinase PKR: Virus and cell control.
Biochimie. 89(6-7):799-811.

Fraile-Ramos A, Pelchen-Matthews A, Risco C, Rejas MT, Emery VC, Hassan-Walker AF, Esteban M and Marsh M. (2007)
The ESCRT machinery is not required for human cytomegalovirus envelopment.
Cell Microbiol. 9(12):2955-2967.

Najera JL, Gomez CE, Domingo-Gil E, Gherardi MM and Esteban M. (2006)
Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene.
J Virol. 80(12):6033-6047.

Guerra S, Lopez-Fernandez LA, Pascual-Montano A, Najera JL, Zaballos A and Esteban M. (2006)
Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kappaB-responsive genes in infected HeLa cells.
J Virol. 80(2):985-998.

Guerra S, Lopez-Fernandez LA, Garcia MA, Zaballos A and Esteban M. (2006)
Human gene profiling in response to the active protein kinase, interferon-induced serine/threonine protein kinase (PKR), in infected cells. Involvement of the transcription factor ATF-3 IN PKR-induced apoptosis.
J Biol Chem. 281(27):18734-18745.

Garcia MA, Gil J, Ventoso I, Guerra S, Domingo E, Rivas C and Esteban M. (2006)
Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action.
Microbiol Mol Biol Rev. 70(4):1032-1060.

Abaitua F, Rodriguez JR, Garzon A, Rodriguez D and Esteban M. (2006)
Improving recombinant MVA immune responses: Potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Virus Res. 116(1-2):11-20.

Munoz-Fontela C, Angel Garcia M, Garcia-Cao I, Collado M, Arroyo J, Esteban M, Serrano M and Rivas C. (2005)
Resistance to viral infection of super p53 mice.
Oncogene. 24(18):3059-3062.

Guerra S, Aracil M, Conde R, Bernad A and Esteban M. (2005)
Wiskott-Aldrich syndrome protein is needed for vaccinia virus pathogenesis.
J Virol. 79(4):2133-2140.

Gonzalez B, Reina R, Garcia I, Andres S, Glaria I, Alzueta M, Mora MI, Jugo BM, Arrieta-Aguirre I, de la Lastra JM, Rodriguez D, Rodriguez JR, Esteban M, Grillo MJ, Blacklaws BA, Harkiss GD, Chebloune Y, Lujan L, de Andres D and Amorena B. (2005)
Mucosal immunization of sheep with a Maedi-Visna virus (MVV) env DNA vaccine protects against early MVV productive infection.
Vaccine. 23(34):4342-4352.

Gomez CE, Vandermeeren AM, Garcia MA, Domingo-Gil E and Esteban M. (2005)
Involvement of PKR and RNase L in translational control and induction of apoptosis after Hepatitis C polyprotein expression from a vaccinia virus recombinant.
Virol J. 2:81.

Gherardi MM and Esteban M. (2005)
Recombinant poxviruses as mucosal vaccine vectors.
J Gen Virol. 86(Pt 11):2925-2936.

Dondji B, Perez-Jimenez E, Goldsmith-Pestana K, Esteban M and McMahon-Pratt D. (2005)
Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis.
Infect Immun. 73(8):5286-5289.

Cyrklaff M, Risco C, Fernandez JJ, Jimenez MV, Esteban M, Baumeister W and Carrascosa JL. (2005)
Cryo-electron tomography of vaccinia virus.
Proc Natl Acad Sci U S A 102:2772-2777.

Alcami J, Joseph Munne J, Munoz-Fernandez MA and Esteban M. (2005)
Current situation in the development of a preventive HIV vaccine.
Enferm Infecc Microbiol Clin. 23(Supl. 2):15-24.

Alcami J, Joseph Munne J, Munoz-Fernandez MA and Esteban M. (2005)
[Present situation in the development of a preventive HIV vaccine.].
Enferm Infecc Microbiol Clin. 23(Suppl. 2):5-14.